Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Moderate Buy” by Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $9.75.

A number of brokerages have recently commented on ACRS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 22nd. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a research report on Monday, October 20th.

Aclaris Therapeutics Trading Down 0.3%

ACRS opened at $3.03 on Monday. The company has a market cap of $328.30 million, a P/E ratio of -2.20 and a beta of 0.62. The company’s 50 day moving average is $2.68 and its 200-day moving average is $2.06. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $3.47.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. The business had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $1.59 million. On average, equities analysts forecast that Aclaris Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC grew its holdings in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after acquiring an additional 2,175,101 shares during the last quarter. Geode Capital Management LLC increased its holdings in Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 1,282,042 shares during the period. Acadian Asset Management LLC raised its position in Aclaris Therapeutics by 10.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock worth $3,453,000 after purchasing an additional 238,659 shares during the last quarter. Palo Alto Investors LP lifted its holdings in Aclaris Therapeutics by 12.7% during the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 176,812 shares during the period. Finally, Citadel Advisors LLC lifted its holdings in Aclaris Therapeutics by 25.3% during the 3rd quarter. Citadel Advisors LLC now owns 1,432,677 shares of the biotechnology company’s stock worth $2,722,000 after buying an additional 288,871 shares during the period. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.